Skip to Main Content

In a rare move, the BBB National Programs settled a dispute between two big drug companies over a prescription drug ad, suggesting the nonprofit may take a larger role in resolving complaints that might normally be handled by the U.S. Food and Drug Administration.

The dispute began when Eli Lilly challenged some of the information in an ad that Novartis had run for its Kisqali breast cancer treatment. Specifically, Lilly objected to language about the overall survival rate in Kisqali clinical trials that suggested the drug was superior to similar cancer medications. Lilly markets a breast cancer medicine called Verzenio.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment